Cargando…

Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition—A Pooled Analysis of Patients With Advanced Melanoma

PURPOSE: Outcome measures that comprehensively capture attributes of immuno-oncology agents, including prolonged treatment-free time and persistent treatment-related adverse events (TRAEs), are needed to complement conventional survival end points. METHODS: We pooled data from the CheckMate 067 and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Regan, Meredith M., Werner, Lillian, Rao, Sumati, Gupte-Singh, Komal, Hodi, F. Stephen, Kirkwood, John M., Kluger, Harriet M., Larkin, James, Postow, Michael A., Ritchings, Corey, Sznol, Mario, Tarhini, Ahmad A., Wolchok, Jedd D., Atkins, Michael B., McDermott, David F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Clinical Oncology 2019
Materias:	Original Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6901280/ https://www.ncbi.nlm.nih.gov/pubmed/31498030 http://dx.doi.org/10.1200/JCO.19.00345

Ejemplares similares

Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067
por: Regan, Meredith M, et al.
Publicado: (2021)

Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors
por: Mantia, Charlene M., et al.
Publicado: (2021)

CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
por: Callahan, Margaret K., et al.
Publicado: (2015)

Ipilimumab in patients with melanoma and autoimmune disease
por: Kyi, Chrisann, et al.
Publicado: (2014)

Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma
por: Homicsko, Krisztian, et al.
Publicado: (2022)

Opportunistic infections in patients treated with immunotherapy for cancer
por: Kyi, Chrisann, et al.
Publicado: (2014)

Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment()
por: Cassidy, Michael R., et al.
Publicado: (2017)

Immuno-oncology safety education experience: Key lessons from ipilimumab (IPI)
por: Bartell, Heddy, et al.
Publicado: (2015)

Combination immunotherapy: a road map
por: Ott, Patrick A., et al.
Publicado: (2017)

A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma(☆)
por: Tarhini, A.A., et al.
Publicado: (2021)

Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab
por: Topalian, Suzanne L., et al.
Publicado: (2019)

T cell receptor diversity evaluation to predict patient response to Ipilimumab in metastatic melanoma
por: Postow, Michael, et al.
Publicado: (2014)

Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab
por: Postow, Michael A, et al.
Publicado: (2014)

Patterns of long-term survival following Ipilimumab (Ipi): the Memorial Sloan Kettering Cancer Center 10-year metastatic melanoma (MM) experience
por: Page, David B, et al.
Publicado: (2014)

Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment
por: Anderson, Erik S., et al.
Publicado: (2017)

Improved Endpoints for Cancer Immunotherapy Trials
por: Hoos, Axel, et al.
Publicado: (2010)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

Pre-treatment serum vascular endothelial growth factor is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab
por: Yuan, Jianda, et al.
Publicado: (2013)

PD-1 as a potential target in cancer therapy
por: McDermott, David F, et al.
Publicado: (2013)

Indirect Treatment Comparison of Nivolumab Versus Observation or Ipilimumab as Adjuvant Therapy in Resected Melanoma Using Pooled Clinical Trial Data
por: Freeman, Morganna, et al.
Publicado: (2019)

Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors
por: Aziz, Saadia A, et al.
Publicado: (2013)

Health-related quality of life results from the phase III CheckMate 067 study
por: Schadendorf, Dirk, et al.
Publicado: (2017)

Refusing to TAP out: 16 new human TEIPPs identified
por: Gigoux, Mathieu, et al.
Publicado: (2018)

Management of metastatic renal cell carcinoma in patients with poor prognosis
por: Bullock, Andrea, et al.
Publicado: (2010)

Tumor antigens for cancer immunotherapy: therapeutic potential of xenogeneic DNA vaccines
por: Srinivasan, Roopa, et al.
Publicado: (2004)

Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer
por: Zamarin, Dmitriy, et al.
Publicado: (2014)

Immunotherapy and the belly of the beast
por: Merghoub, Taha, et al.
Publicado: (2014)

Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma
por: Postow, Michael A., et al.
Publicado: (2015)

A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma
por: Slingluff, Craig L., et al.
Publicado: (2021)

Myeloid-derived suppressor cells and the efficacy of CD8(+) T-cell immunotherapy
por: Lesokhin, Alexander M., et al.
Publicado: (2013)

Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors
por: Mamoor, Maha, et al.
Publicado: (2020)

Vascularity of primary and metastatic renal cell carcinoma specimens
por: Aziz, Saadia A, et al.
Publicado: (2013)

Direct comparisons of T cell costimulation and checkpoint blockade in the setting of tumor-targeted monoclonal antibody therapy
por: Khalil, Danny, et al.
Publicado: (2015)

Shared cancer neoantigens: Making private matters public
por: Klebanoff, Christopher A., et al.
Publicado: (2018)

The many faces of the anti-COVID immune response
por: Vardhana, Santosha A., et al.
Publicado: (2020)

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
por: Wolchok, Jedd D., et al.
Publicado: (2022)

Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma
por: Rosner, Samuel, et al.
Publicado: (2018)

Hiding the road signs that lead to tumor immunity
por: Schaer, David A., et al.
Publicado: (2011)

Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy
por: Hughes, Jing, et al.
Publicado: (2015)

CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of (89)Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody
por: Farwell, Michael D., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5m934o8s8v798d6r1pao7fr33h